Key facts
- Compass Pathways stock price dropped significantly.
- The decline followed the release of Phase IIb trial data for psilocybin therapy.
- The therapy showed statistically significant improvement in depression symptoms.
- The therapy did not meet its primary endpoint for remission.
- The trial targeted treatment-resistant depression.
Compass Pathways (CMPS) saw its stock price plummet today after the company disclosed results from its Phase IIb clinical trial investigating psilocybin therapy for treatment-resistant depression. While the therapy demonstrated a statistically significant improvement in depression symptoms compared to a placebo, it failed to achieve its primary endpoint of remission at week six. The trial involved 233 participants across 10 sites in Europe and North America. The company stated that the data suggests psilocybin therapy can provide rapid and sustained antidepressant effects. However, the failure to meet the primary remission endpoint appears to have spooked investors, leading to the sharp sell-off in the company's shares.